TY  - GEN
AU  - Petrylak,Daniel P
AU  - Gandhi,Jitendra G
AU  - Clark,William R
AU  - Heath,Elisabeth
AU  - Lin,Jianqing
AU  - Oh,William K
AU  - Agus,David B
AU  - Carthon,Bradley
AU  - Moran,Susan
AU  - Kong,Ning
AU  - Suri,Ajit
AU  - Bargfrede,Michael
AU  - Liu,Glenn
TI  - Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer
SN  - 1573-0646
PY  - 2016///0119
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Dehydroepiandrosterone Sulfate
KW  - blood
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - Dose-Response Relationship, Drug
KW  - Humans
KW  - Imidazoles
KW  - Male
KW  - Middle Aged
KW  - Naphthalenes
KW  - Prednisone
KW  - Prostate-Specific Antigen
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - drug therapy
KW  - Steroid 17-alpha-Hydroxylase
KW  - antagonists & inhibitors
KW  - Taxoids
KW  - Testosterone
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s10637-014-0199-x
ER  -